Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.60 |
| ▸ | FNTA | P49354 | 10/20 | 0.47 |
| ▸ | FNTB | P49356 | 10/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658010 | 0.91 | CYP11B1 (0.53) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL2789879 | 0.85 | CYP11B1 (0.47) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7194363 | 0.85 | CYP11B1 (0.57) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8005944 | 0.84 | CYP11B1 (0.56) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3501417 | 0.82 | FNTA (0.62) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL6433915 | 0.81 | CYP11B1 (0.64) | CYP11B1CYP11B2CACNA1H | |
| SCHEMBL7658006 | 0.81 | FNTA (0.47) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Hydrochloric Acid SCHEMBL7980481 | 0.81 | FNTA (0.61) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7187767 | 0.80 | CYP11B1 (0.60) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7585827 | 0.77 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6103487-A | DETECTING MODULATORS THAT SUPPRESS THE ACTIVITY OF A TRANSFERASES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-1019529-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000016626-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | CYP11B1 530/4885CYP11B2 621/4885FNTA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.